Emvolio is developing products
that can be used together to attack cancer at different
levels,
as well as be used alone or in combination with existing
therapies.
OCEANSIDE, CA -- May 1, 2017 -- InvestorsHub NewsWire --
Therapeutics Solutions International, Inc., (OTC
PINK: TSOI)
announced today that the Board of Directors of its majority owned
subsidiary, Emvolio, Inc. (Emvolio) has appointed Thomas E. Ichim,
PhD, as Chief Executive Officer of Emvolio.
Dr. Ichim is a seasoned biotechnology entrepreneur with a track
record of scientific excellence. He has founded/co-founded several
companies including Batu Biologics, Inc., Medvax Pharma Corp,
ToleroTech Inc, bioRASI, and OncoMune LLC. To date he has published
over 100 peer-reviewed articles and is co-editor of the textbooks
RNA Interference: From Bench to Clinical Translation and
Immuno-Oncology Text Book.
Dr. Ichim is an ad-hoc editor and sits on several editorial
boards. Dr Ichim is inventor on over 50 patents and patent
applications. Dr. Ichim has extensive experience with stem cell
therapy and cellular product development through FDA regulatory
pathways. Dr. Ichim spent over 7 years as the President and Chief
Scientific Officer of Medistem, developing and commercializing a
novel stem cell, the Endometrial Regenerative Cell, through drug
discovery, optimization, preclinical testing, IND filing, and up
through Phase II clinical trials with the FDA. Dr. Ichim has
extensive experience in product development, regulatory filings,
and business development.
Dr. Ichim has a BSc in Biology from the University of Waterloo,
Waterloo, Ontario, Canada, a MSc in Microbiology and Immunology a
University of Western Ontario, London, Ontario, Canada and a Ph.D
in Immunology from the University of Sciences Arts and Technology,
Olveston Monserrat.
"Both the Board of Directors of TSOI and Emvolio are ecstatic
about the appointment of Dr. Ichim as CEO of Emvolio. Having Dr.
Ichim to guide the maturation and implementation of our
intellectual property of which he is co-inventor, gives us the best
possible outcome for development of our immune-oncology technology
licensed to Emvolio by TSOI", said Timothy Dixon, Chairman of
Emvolio and Chairman and CEO of Therapeutic Solutions
International.
"Emvolio previous announced on April 12th the filing of an
Investigational New Drug (IND) application # 17448 with the FDA on
its StemVacs cancer immunotherapeutic in patients with solid
tumors. (http://www.marketwired.com/press-release/-2209423.htm)
Dr. Ichim will lead the Company in all phases in its research and
development of this new immunotherapeutic", said Gerry Berg, Vice
President and CFO of Emvolio and Therapeutic Solutions
International. We are pleased to welcome him to the executive
team.
About Therapeutic Solutions International,
Inc.
The Company's corporate website is www.therapeuticsolutionsint.com.
About Emvolio, Inc.
The Company's corporate website is www.emvolio.com.
Safe Harbor Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. The reader is cautioned not
to put undue reliance on these forward-looking statements, as these
statements are subject to numerous risk factors as set forth in our
SEC filings. To the extent that statements in this press release
are not strictly historical, including statements as to product
launch timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements made.
CONTACT INFORMATION
Therapeutic Solutions International, Inc.
ir@tsoimail.com